Barclays PLC Buys 239,650 Shares of Stryker Corporation $SYK

Barclays PLC lifted its stake in Stryker Corporation (NYSE:SYK) by 25.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,168,656 shares of the medical technology company’s stock after purchasing an additional 239,650 shares during the period. Barclays PLC’s holdings in Stryker were worth $410,748,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Aigen Investment Management LP boosted its holdings in shares of Stryker by 188.2% in the fourth quarter. Aigen Investment Management LP now owns 3,375 shares of the medical technology company’s stock worth $1,186,000 after acquiring an additional 2,204 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Stryker by 1,925.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 454,965 shares of the medical technology company’s stock worth $159,907,000 after acquiring an additional 432,498 shares during the period. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the fourth quarter worth $27,000. Burton Enright Welch bought a new position in shares of Stryker in the fourth quarter worth $607,000. Finally, Kestra Advisory Services LLC raised its position in shares of Stryker by 3.7% in the fourth quarter. Kestra Advisory Services LLC now owns 84,909 shares of the medical technology company’s stock worth $29,843,000 after buying an additional 3,063 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Stock Up 2.1%

Shares of NYSE:SYK opened at $312.14 on Friday. The stock’s 50-day moving average price is $316.40 and its 200-day moving average price is $343.97. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The stock has a market capitalization of $119.66 billion, a P/E ratio of 36.13, a price-to-earnings-growth ratio of 1.97 and a beta of 0.78. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period last year, the business posted $2.84 earnings per share. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SYK. Barclays lowered their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Citigroup lowered their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Robert W. Baird set a $385.00 price objective on Stryker in a research report on Friday, May 1st. The Goldman Sachs Group reiterated a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, Canaccord Genuity Group lowered their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $395.33.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.